Oct. 21, 2025 -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, dosed first patients in its two randomized, double-blind, multicenter global Phase 3 trials, the RUBY study (NCT07089875) and the TOPAZ study (NCT07089888), evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor with potential for bes

Oct. 19, 2025 -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P) The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment wit

IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studies First patient dosing planned before year-end 2025 at leading cancer centers in collaboration with top key opinion leaders Program validates Dewpoint’s condensate-modulator discovery platform and the value of agile, integrated partnerships in accelerating novel drug development. Oct. 21, 2025 -- Dewpoint Therapeutics today announced the opening of an I

Oct. 20, 2025 -- Adaptyx Biosciences, a biowearables company developing the first platform for continuous, multi-analyte molecular monitoring, today announced it has raised $14 million in seed financing, bringing total funding to $23 million since inception. The round was led by Interlagos, with significant participation from Overwater Ventures, and joined by Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Vent

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients In the 120 mg palazestrant cohort among patients with prior CDK4/6i treatment, median PFS was 9.2 months in patients with ESR1 wild-type tumors and 13.8 months in patients with ESR1 mutant tumors Combination continues to demonstrate favorable tolerability and a safety profile consistent with the known

Novel mechanism of action reverses and prevents death of injured cells Phase II ARPEGGIO trial fully enrolled Topline results to be presented at the World Stroke Congress, October 23, 2025 Oct. 17, 2025 -- Silver Creek Pharmaceuticals, Inc. (Silver Creek), a clinical-stage biotechnology company developing growth factor-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to scp776, its investigational therapy for acute ischemic

TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models Data support advancement of TNX-801 toward clinical development Oct. 17, 2025 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”) presented data in an oral presentation at the World Vaccine Congress–Europe 2025, held October 14–16, 20

Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response by blinded independent central review was 77%, with 96% of patients achieving disease control.1 Zongertinib recently received Breakthrough Therapy Designations for first-line treatment by the U.S. FDA and China’s CDE. Boehringer Ingelheim reported positive results from the Beamion LUNG-1 trial ev

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival of approximately 12 months for patients with extensive-stage disease Precede Bio’s platform combines comprehensive epigenomic profiling of circulating tumor DNA (ctDNA) with machine learning to resolve gene expression for thousands of cancer genes from just 1 mL of patient plasma Data presented at ESMO 2025 highlight the platform’s ability to resolve the expression of clinica

BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the nebulizer has also been addressed In parallel, new written FDA feedback underscores the significant unmet need BiomX is addressing and outlines new potential development approaches European enrollment and dosing remain strong; Phase 2b study remains on track to report topline resul